Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
3
Neutral
5
Bullish
6
Bearish
20
Neutral
5
Bullish
21
Bearish
17
Neutral
0
Bullish
15
Discovery themes featuring this stock
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q2 FY21
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY21
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Ind-Swift Laboratories Ltd is a pharmaceutical manufacturer repositioned as a pure‑play Finished Dosage Formulations (FDF) company focused on exports, contract manufacturing (CDMO/CMO) and domestic branded/ethical therapies, operating two accredited manufacturing sites (Derabassi EOU and Samba) and an R&D centre supporting regulated‑market dossiers and tech transfers.
The company completed a strategic reset by divesting its capital‑intensive API & CRAMS business for ₹1,650 Cr, repaying all external debt and emerging as a net‑debt‑free formulations platform with a retained 7.8% stake in the buyer, materially improving balance sheet flexibility for growth investments.
Commercialisation with Viatris and other long‑term CMO partners is a key growth catalyst: Ind‑Swift expects commercial supplies to Viatris to begin FY27 and to contribute roughly ₹200–220 Cr incremental revenue, materially accelerating the Global Business Unit and CDMO revenue trajectory.
Ind‑Swift has a deep dossier and approvals footprint—1,915+ dossiers filed and 520+ global approvals—combined with Derabassi capacity capable of supporting >₹10 billion revenue, giving the company visibility to scale exports, launch 400+ new registrations by 2026, and pursue regulated‑market launches and out‑licensing opportunities.
Near‑term financial momentum shows stable quarterly revenues (~₹177 Cr Q3 FY26 total revenue) with improving operating EBITDA margins (5.95% Q3 FY26) and sequential PAT growth of 22.6% quarter‑on‑quarter, reflecting cost efficiencies and non‑operating income variability amid the post‑transformation phase.
Pharmaceuticals
Pharmaceuticals - Indian - Bulk Drugs & Formln M/S
1,118 Cr
Moderate Risk
5.0
28.4
—
0.9
151.95
67.15
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Ind-Swift Laboratories Ltd (INDSWFTLAB) is currently trading at 126.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Ind-Swift Laboratories Ltd is a pharmaceutical manufacturer repositioned as a pure‑play Finished Dosage Formulations (FDF) company focused on exports, contract manufacturing (CDMO/CMO) and domestic branded/ethical therapies, operating two accredited manufacturing sites (Derabassi EOU and Samba) and an R&D centre supporting regulated‑market dossiers and tech transfers. The company completed a strategic reset by divesting its capital‑intensive API & CRAMS business for ₹1,650 Cr, repaying all external debt and emerging as a net‑debt‑free formulations platform with a retained 7.8% stake in the buyer, materially improving balance sheet flexibility for growth investments. Commercialisation with Viatris and other long‑term CMO partners is a key growth catalyst: Ind‑Swift expects commercial supplies to Viatris to begin FY27 and to contribute roughly ₹200–220 Cr incremental revenue, materially accelerating the Global Business Unit and CDMO revenue trajectory. Ind‑Swift has a deep dossier and approvals footprint—1,915+ dossiers filed and 520+ global approvals—combined with Derabassi capacity capable of supporting >₹10 billion revenue, giving the company visibility to scale exports, launch 400+ new registrations by 2026, and pursue regulated‑market launches and out‑licensing opportunities. Near‑term financial momentum shows stable quarterly revenues (~₹177 Cr Q3 FY26 total revenue) with improving operating EBITDA margins (5.95% Q3 FY26) and sequential PAT growth of 22.6% quarter‑on‑quarter, reflecting cost efficiencies and non‑operating income variability amid the post‑transformation phase.
Over the past 52 weeks, Ind-Swift Laboratories Ltd has traded between a low of ₹67.15 and a high of ₹151.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Ind-Swift Laboratories Ltd has a market capitalization of approximately 1,118.49. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Ind-Swift Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 4.99 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,118.49 Cr, Ind-Swift Laboratories Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Ind-Swift Laboratories Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Ind-Swift Laboratories Ltd is 4.99. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
521.45 | 1,166 Cr | 45.93 | 3.85 | 0.00 | 6.43 | 8.43 | 5.62 | |
126.20 | 1,118 Cr | 4.99 | 0.86 | 0.00 | 2.27 | 1.19 | 16.09 | |
170.50 | 1,090 Cr | 28.12 | 4.31 | 1.52 | 17.30 | 21.58 | 13.68 | |
321.15 | 1,026 Cr | 20.80 | 2.11 | 0.31 | 10.52 | 10.52 | 5.94 | |
243.00 | 884 Cr | 20.48 | 11.41 | 0.00 | 51.51 | 27.98 | 10.39 | |
331.90 | 829 Cr | 21.13 | 3.53 | 0.29 | 13.89 | 19.49 | 12.00 | |
19.50 | 759 Cr | -10.00 | 1.50 | 0.50 | 12.11 | 12.71 | -8.73 |
Regulatory Filing
Ind‑Swift Laboratories' 100% export Global Business Unit received an EcoVadis Silver Medal (top 15% globally) alongside multiple international certifications, strengthening its ESG credentials and market access.
Regulatory Filing
Ind‑Swift Laboratories’ Global Business Unit (100% EOU, Derabassi) received an EcoVadis Silver Medal (top 15% globally) and reaffirmed multiple certifications (SMETA, ISO 14001/45001/27001/37001) in a Reg 30 filing.
Warrant Forfeiture
Ind‑Swift Labs reports that 6,500,000 fully convertible warrants allotted to Saral Incorporated VCC Sub Fund 1 lapsed on Feb 28, 2026, and the upfront subscription of ₹19,66,25,000 has been forfeited; 19,500,000 warrants were earlier converted.
Substantial Acquisition
Essix Biosciences (on behalf of promoter & PACs) converted 5,100,000 fully‑convertible warrants into equity and acquired 51,00,000 shares of Ind‑Swift Laboratories (NSE: INDSWFTLAB; BSE:532305) on Feb 24, 2026; regulatory disclosure filed.
Substantial Acquisition
Essix Biosciences, on behalf of the promoter & promoter group, acquired 5,100,000 equity shares of Ind‑Swift Laboratories on Feb 24, 2026 via conversion of fully convertible warrants; disclosed under Reg.29(2) SEBI (SAST).
